Swiss Life Asset Management Ltd Sells 11,567 Shares of Boston Scientific Corporation $BSX

Swiss Life Asset Management Ltd lowered its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 6.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 159,672 shares of the medical equipment provider’s stock after selling 11,567 shares during the period. Swiss Life Asset Management Ltd’s holdings in Boston Scientific were worth $15,589,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of BSX. Strategic Advocates LLC lifted its holdings in Boston Scientific by 12.6% during the 3rd quarter. Strategic Advocates LLC now owns 24,107 shares of the medical equipment provider’s stock valued at $2,354,000 after purchasing an additional 2,697 shares during the last quarter. CIBC Private Wealth Group LLC lifted its position in Boston Scientific by 0.7% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,387,686 shares of the medical equipment provider’s stock worth $135,480,000 after buying an additional 9,670 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in Boston Scientific in the 3rd quarter valued at about $59,002,000. Caerus Investment Advisors LLC bought a new position in shares of Boston Scientific in the third quarter worth about $247,000. Finally, Coldstream Capital Management Inc. raised its stake in shares of Boston Scientific by 15.5% in the third quarter. Coldstream Capital Management Inc. now owns 43,512 shares of the medical equipment provider’s stock worth $4,248,000 after acquiring an additional 5,839 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Truist kept a “buy” rating while trimming its price target to $92, signifying continued analyst confidence in BSX’s longer-term growth despite a modest cut to near-term expectations. Read More.
• Positive Sentiment: Analyst commentary and screeners continue to list Boston Scientific as a defensive healthcare pick amid broader market volatility, supporting demand from investors seeking lower-correlation names. Read More.
• Neutral Sentiment: Health-care indices were softer in late trading today, which weighs on BSX alongside peers but reflects sector-wide pressure rather than company-specific fundamentals. Read More.
• Neutral Sentiment: Relative performance: Boston Scientific underperformed some competitors in today’s session, signalling short-term selling pressure versus the group. Read More.
• Negative Sentiment: Boston Scientific amended its recall for Accolade pacemakers, expanding the affected population to about 1.6 million devices and updating related software remediation — a material safety/recall development that raises regulatory, replacement and reputational risks. Read More.
• Negative Sentiment: The New York Times reported Boston Scientific had internal test results in 2025 showing an “extremely high failure rate” for some pacemaker batteries and that management knew of battery problems for years — a disclosure likely increasing litigation and regulatory scrutiny. Read More.
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs in securities-class-action lawsuits tied to disclosures (class period Jul 23, 2025–Feb 3, 2026), and several investor-alerts remind shareholders of an early-May deadline to seek lead-plaintiff status — increasing legal risk and potential costs. Read More.
• Negative Sentiment: Additional analyst downgrades/expectation cuts (UBS among them) have lowered near-term estimates, compounding downward pressure on the stock while investors reassess guidance and litigation/recall impacts. Read More.

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on BSX shares. Mizuho dropped their price objective on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Citigroup lowered their target price on Boston Scientific from $102.00 to $94.00 and set a “buy” rating for the company in a research note on Wednesday, March 11th. Morgan Stanley cut their price target on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Evercore decreased their price target on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Finally, TD Cowen lowered their price objective on Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Boston Scientific has a consensus rating of “Buy” and an average target price of $107.18.

Boston Scientific Stock Performance

BSX opened at $70.04 on Friday. The company has a market capitalization of $103.93 billion, a price-to-earnings ratio of 36.10, a P/E/G ratio of 1.00 and a beta of 0.69. The business’s 50-day moving average price is $80.31 and its two-hundred day moving average price is $92.40. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. Boston Scientific Corporation has a 1 year low of $67.56 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same period last year, the business earned $0.70 EPS. The business’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.